Recce Pharmaceuticals will partner with the United States Army to test its anti-infective medications, with the goal of treating drug-resistant infections.
The U.S. Army’s Medical Research Institute of Infectious Diseases (USAMRIID), which explores countermeasures against dangerous pathogens and biological warfare, will test the synthetic anti-infective drug Recce 327 with funding from the U.S. Defense Threat Reduction Agency (DTRA).
“We are thrilled to enter into another U.S. Department of Defense Research program, this time with the United States Army Medical Research Institute of Infectious Diseases and are very thankful for our partners at USAMRIID and DTRA,” Recce CEO James Graham said.
“This program will see the U.S. Army test R327 [Recce 327] against some of the world’s deadliest pathogens and comes in addition to an ongoing DoD [Department of Defense] burn wound program, further bolstering Recce’s on-going U.S. Government partnerships.”
Recce 327 will first be tested against USAMRIID’s in vitro infection models, and then on small animal models.
The medication is effective against otherwise drug-resistant bacteria, according to Recce.
The company’s 327G treatment, a topical gel version of the 327 drug, has also received a US$2 million grant from the U.S. Department of Defense to speed up its development.
Recce is about to begin 327G trials in Indonesia for diabetic foot infections, and will run trials in Australia later in 2025. This could lead to the drug’s commercial launch in Southeast Asia in the second half of 2026, the company said. Previous trials showed 86% of patients improvement after seven days of treatment.
Recce Pharmaceuticals’ (ASX: RCE) share price stands at $0.29 as of writing, flat from its previous close. Its market capitalisation is $83.63 million.
